Patient Experience with 10 mg Intranasally Administered Zavegepant as an Acute Treatment of Migraine Attacks: Qualitative Research Findings.

Migraine is a significant burden on individuals and healthcare systems alike. This study investigates patient experiences with zavegepant 10 mg intranasal for acute migraine treatment. Adults with self-reported migraines used zavegepant in the past three months. They participated in in-depth interviews to discuss treatment experiences. Participants were recruited through a research panel for these interviews. They shared their usage patterns and treatment outcomes during the discussions. Many patients completed a point allocation exercise, ranking zavegepant features by importance. Fifteen patients aged 23 to 63 participated in this study. Zavegepant was generally seen as effective, fast-acting, and convenient. Patients often chose zavegepant for severe attacks or when needing to continue activities. Some reported a bitter, metallic taste but still preferred zavegepant. Most valued effectiveness and improvements in physical and emotional well-being. Findings highlight the need for better education on administration techniques and side effects. Clinical relevance: This research suggests that effective patient education on zavegepant use could enhance treatment outcomes for migraine patients.